Skip to main content
SpringerLink
Log in

Bioequivalence for Topical Drug Products

  • Chapter
  • First Online:
FDA Bioequivalence Standards

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 13))

  • 3136 Accesses

Abstract

This chapter discusses the current approaches for bioequivalence (BE) assessment of generic topical drug products by the United States Food and Drug Administration (US FDA). The approval of these drug products are governed by guidances and federal regulations that facilitate the development and subsequent approval of bioequivalent topical drug products. The goal is for these generic topical drug products to be therapeutically equivalent to the innovator (reference) product. The variation in the site of activity, multiple dosage forms (vehicles), and therapeutic drug classes are all critical factors in the determination of appropriate scientific/clinical approaches that are most suitable to demonstrate BE between the generic and reference product. The most common type of topical drug products is considered to be locally acting dermatologic drug products. So, establishing BE has been a daunting task due to the site of action commonly being in or on the skin. In most cases, BE studies with clinical endpoints are recommended for topical drug products, except for in the case of topical dermatologic corticosteroids in which in vivo pharmacodynamic studies are recommended. Despite these limitations, the US FDA is forging ahead through regulatory science initiatives and collaborative research projects to explore the progression of new in vitro and/or in vivo methods; along with improvement of the current approaches used for BE assessment of generic topical drug products.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Anderson C, Andersson T, Molander M (1991) Ethanol absorption across human skin measured by in vivo microdialysis technique. Acta Derm Venereol 71(5):389–393

    CAS  PubMed  Google Scholar 

  • Au WL, Skinner MF, Benfeldt E, Verbeeck RK, Kanfer I (2012) Application of dermal microdialysis for the determination of bioavailability of clobetasol propionate applied to the skin of human subjects. Skin Pharmacol Physiol 25(1):17–24

    Article  CAS  PubMed  Google Scholar 

  • Boix-Montanes A (2011) Relevance of equivalence assessment of topical products based on the dermatopharmacokinetics approach. Eur J Pharm Sci 42(3):173–1796

    Article  CAS  PubMed  Google Scholar 

  • Braddy AC, Conner DP (2011) Regulatory Perspective of Dermatokinetic Studies. In: Murthy SN (ed) Dermatokinetic of therapeutic agents. CRC, Boca Raton, pp 193–201

    Chapter  Google Scholar 

  • Buxton ILO (2006) Pharmacokinetic and pharmacodynamics: the dynamics of drug absorption, distribution, action and elimination. In: Brunton LL, Lazo JS, Parker KL (eds) Goodman & Gilman’s The pharmacological basis of therapeutics, 11th edn. McGraw-Hill, New York, pp 1–39

    Google Scholar 

  • Chang RK, Raw A, Lionberger R, Yu L (2013a) Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products. AAPS J 15(1):41–52

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chang RK, Raw A, Lionberger R, Yu L (2013b) Generic development of topical dermatologic products, part II: quality by design for topical semisolid products. AAPS J 15(3):674–682

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J et al (2007) AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res 24(5):1014–1025

    Article  CAS  PubMed  Google Scholar 

  • Critical Path Opportunities for Generic Drugs (2007) U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077250.htm. Accessed 18 Nov 2013

  • Electronic Orange Book (2013) U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD. http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Accessed 18 Nov 2013

  • Federal Register (2002) Draft guidance for industry on topical dermatological drug product NDAs and ANDAs—In vivo bioavailability, bioequivalence, in vitro release and associated studies; withdrawal [Docket No. 98D-0388]. U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD. https://www.federalregister.gov/articles/1998/06/18/98-16141/draft-guidance-for-industry-on-topical-dermatological-drug-product-ndas-and-andasin-vivo. Accessed 18 Nov 2013

  • Federal Register (2008) Publication of guidances for industry describing product-specific bioequivalence recommendations [Docket No. FDA 2007-D-0369]. U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD. https://www.federalregister.gov/articles/2008/09/05/E8-20580/publication-of-guidances-for-industry-describing-product-specific-bioequivalence-recommendations. Accessed 18 Nov 2013

  • Federal Register (2012) Drugs for human use; drug efficacy study implementation; certain prescription drugs offered for various indications; opportunity to affirm outstanding hearing request. U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Silver Spring, MD. https://www.federalregister.gov/articles/2012/07/24/2012-18015/drugs-for-human-use-drug-efficacy-study-implementation-certain-prescription-drugs-offered-for. Accessed 18 Nov 2013

  • Franz TJ, Lehman PA, Raney SG (2009) Use of excised human skin to assess the bioequivalence of topical products. Skin Pharmacol Physiol 22(5):276–286

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • General Chapter <1151> Pharmaceutical Dosage Forms (2013) U.S. Pharmacopeia, Rockville, MD. http://www.uspnf.com/uspnf/pub/index?usp=36&nf=31&s=1&officialOn=August1,2013. Accessed 18 Nov 2013

  • General Chapter <1059> Excipient Performance (2013). U.S. Pharmacopeia, Rockville. http://www.uspnf.com/uspnf/pub/index?usp=36&nf=31&s=1&officialOn=August%201,%202013. Accessed 18 Nov 2013

  • Generic Drug User Fee Act Program Performance Goals and Procedure (2012) U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/ForIndustry/UserFees/GenericDrugUserFees/UCM282505.pdf. Accessed 18 Nov 2013

  • Generic Drug User Fee Amendments (2012) U.S. Food and Drug Administration Safety and Innovation Act, S.3187. 3187. U.S. Government Printing Office, Washington. http://www.gpo.gov/fdsys/pkg/BILLS-112s3187enr. Accessed 18 Nov 2013

  • Gotter B, Faubel W, Neubert RHH (2008) Optical methods for measurements of skin penetration. Skin Pharmacol Physiol 21(3):151–156

    Article  Google Scholar 

  • Groth L, Garcia OP, Benfeldt E (2006) Microdialysis methodology for sampling in the skin. In: Serup J, Jemec GBE, Grove GL (eds) Handbook of non-invasive methods and the skin, 2nd edn. CRC, Boca Raton, pp 443–454

    Chapter  Google Scholar 

  • Guidance for Industry (1995) topical dermatologic corticosteroids: In vivo bioequivalence (1995) US Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070234.pdf. Accessed 18 Nov 2013

  • Guidance for Industry (1997) Nonsterile semisolid dosage forms, scale-up and post-approval changes: Chemistry, manufacturing, and control; In vitro release resting and in vivo bioequivalence documentation. US Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070930.pdf. Accessed 18 Nov 2013

  • Guidances (2012) Bioequivalence recommendations for Acyclovir Ointment. U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM296733.pdf. Accessed 18 Nov 2013

  • Guidances (2013) Bioequivalence recommendations for specific drug products. U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm. Accessed 18 Nov 2013

  • Handbook of Pharmaceutical Excipients Association (2012) Rowe RC, Sheskey P, Cook WG, Fenton ME (2012) 7th edn. Pharmaceutical Press and American Pharmacists (Online edition-Medicines Complete, http://www.medicinescomplete.com/mc/)

  • Harding CR (2004) The stratum corneum: structure and function in health and disease. Dermatol Ther 17(Suppl 1):6–15

    Article  PubMed  Google Scholar 

  • Holmgaard R, Nielsen JB, Benfeldt E (2010) Microdialysis sampling for investigations of bioavailability and bioequivalence of topically administered drugs: current state and future perspectives. Skin Pharmacol Physiol 23(5):225–243

    Article  CAS  PubMed  Google Scholar 

  • Hueber F, Schaefer H, Weipierre J (1994) Role of transepidermal and transfollicular routes in percutaneous absorption of steroids: in vitro studies on human skin. Skin Pharmacol 75(5):237–244

    Article  Google Scholar 

  • Interim Guidance of Industry (1998) Topical dermatological drug product NDAs and ANDAs—in vivo bioavailability, bioequivalence, in vitro release, and associated studies. U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3661b1c.pdf. Accessed 18 Nov 2013

  • Kircik LH, Bikowski JB, Cohen DE, Draelos ZD, Hebert A (2010) Supplement to practical dermatology—vehicles matter. Formulation development, testing, and approval. Practical Dermatology http://bmctoday.net/vehiclesmatter/pdfs/0310.pdf. Accessed 8 Aug 2013

  • Lademann J, Meinke MC, Schanzer S, Richter H, Darvin ME et al (2012) In vivo methods for the analysis of the penetration of topically applied substances in and through the skin barrier. Int J Cosmet Sci 34(6):551–559

    Article  CAS  PubMed  Google Scholar 

  • Lehman PA, Raney SG, Franz TJ (2011) Percutaneous absorption in man: in vitro-in vivo correlation. Skin Pharmacol Physiol 24(4):224–230

    Article  CAS  PubMed  Google Scholar 

  • Lionberger R (2004) Topical bioequivalence update at: Advisory Committee for Pharmaceutical Science. U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/ohrms/dockets/ac/04/slides/4034s2.htm. Accessed 18 Nov 2013

  • Lionberger R (2008) FDA critical path initiatives: opportunities for generic drug development. AAPS J 10(1):103–109

    Article  PubMed Central  PubMed  Google Scholar 

  • Long CC (2007) Common skin disorders and their topical treatment. In: Walter KA (ed) Dermatological and transdermal formulations. Informa Health Care, New York, pp 41–59

    Google Scholar 

  • Mateus R, Abdalghafor H, Oliveira G, Hadgraft J, Lane ME (2013) A new paradigm in dermatopharmacokinetics—confocal raman spectroscopy. Int J Pharm 444(1–2):106–108

    Article  CAS  PubMed  Google Scholar 

  • McKenzie AW, Stoughton RB (1962) Method for comparing percutaneous absorption of steroids. Arch Dermatol 86(5):608–610

    Article  Google Scholar 

  • Medendorp JP, Paudel KP, Lodder RA, Stinchcomb AL (2007) Near infrared spectrometry for the quantification of human dermal absorption of econazole nitrate and estradiol. Pharm Res 24(1):186–193

    Article  CAS  PubMed  Google Scholar 

  • N’Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL (2008) Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics. Pharm Res 26(2):316–328

    Article  PubMed  Google Scholar 

  • Narkar Y (2010) Bioequivalence for topical products—an update. Pharm Res 27(12):2590–2601

    Article  CAS  PubMed  Google Scholar 

  • National Academy of Sciences (1974) Drug efficacy study of the national research council’s division of medical sciences, 1966–1969. National Academy of Sciences, Washington, DC. http://www.nasonline.org/about-nas/history/archives/collections/des-1966-1969-1.html. Accessed 18 Nov 2013

  • Netzlaff F, Kaca M, Bock U, Haltner-Ukomadu E, Meiers P et al (2007) Permeability of the reconstructed human epidermis model Episkin® in comparison to various human skin preparations. Eur J Pharm Biopharm 66(1):127–134

    Article  CAS  PubMed  Google Scholar 

  • Ortiz PG, Hansen SH, Shah VP, Sonne J, Benfeldt E (2011) Are marketed topical metronidazole creams bioequivalent? evaluation by in vivo microdialysis sampling and tape stripping methodology. Skin Pharmacol Physiol 24(1):44–53

    Article  Google Scholar 

  • Pershing LK, Nelson JL, Corlett JL, Shrivastava S, Hare DB, Shah VP (2003) Assessment of dermatopharmacokinetic approach in the bioequivalence determination of topical tretinoin gel products. J Am Acad Dermatol 48(5):740–751

    Article  PubMed  Google Scholar 

  • Pershing LK, Bakhitan S, Poncelet CE, Corlett JL, Shah VP (2002) Comparison of skin stripping, in vitro release, and skin blanching response methods to measure does response and similarity of triamcinolone acetonide cream strengths from two manufactured sources. J Pharm Sci 91(5):1312–1323

    Article  CAS  PubMed  Google Scholar 

  • Reddy MB, Stinchcomb AL, Guy RH, Bunge AL (2002) Determining dermal absorption parameters in vivo from tape strip data. Pharm Res 19(2):292–298

    Article  CAS  PubMed  Google Scholar 

  • Russell LM, Guy RH (2009) Measurement and prediction of the rate and extent of drug delivery into and through the skin. Expert Opin Drug Deliv 6(4):355–369

    Article  CAS  PubMed  Google Scholar 

  • Saar BG, Contreras-Rojas LR, Xie XS, Guy RH (2011) Imaging drug delivery to skin with stimulated raman scattering microscopy. Mol Pharm 8(3):969–975

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Shah VP, Flynn GL, Yacobi A, Maibach HI, Bon C et al (1998) Bioequivalence of topical dermatological dosage forms—methods of evaluation of bioequivalence. Pharm Res 15(2):167–171

    Article  CAS  PubMed  Google Scholar 

  • Shah VP (2001) Progress in the methodologies for evaluating bioequivalence of topical formulations. Am J Clin Dermatol 2(5):275–280

    Article  CAS  PubMed  Google Scholar 

  • Singh GJP, Adams WP, Lesko LJ, Shah VP, Molzon JA, Williams RL, Pershing LK (1999) Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. Clin Pharmacol Ther 66(4):346–357

    Article  CAS  PubMed  Google Scholar 

  • Stamatas GN (2011) Spectroscopic techniques in dermatokinetic studies. In: Murthy SN (ed) Dermatokinetic of therapeutic agents. CRC, Boca Raton, pp 175–191

    Chapter  Google Scholar 

  • Stoughton RB (1987) Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol 123(10):1312–1314

    Article  CAS  PubMed  Google Scholar 

  • Stoughton RB (1989) Percutaneous absorption of drugs. Annu Rev Pharmacol Toxicol 29:55–69

    Article  CAS  PubMed  Google Scholar 

  • Stoughton RB (1992) Vasoconstrictor assay: specific application. In: Maibach HI, Surber C (eds) Topical corticosteroids. Karger, Switzerland, pp 42–53

    Google Scholar 

  • Tettey-Amlalo RN, Kanfer I, Skinner MF, Benfeldt E, Verbeeck RK (2009) Application of dermal microdialysis for the evaluation of bioequivalence of a ketoprofen topical gel. Eur J Pharm Sci 36(2–3):219–225

    Article  CAS  PubMed  Google Scholar 

  • Topical drug delivery systems. A review (2008) Pharmainfo.net. http://www.pharmainfo.net/reviews/topical-drug-delivery-systems-review. Accessed 18 Nov 2013

  • U.S. Code (1984) The Waxman-Hatch Act. The drug prove competition and patent term restoration act of 1984 (popularly known as the Waxman-Hatch or Hatch-Waxman Act) is codified as 21 U.S.C. 355 of the food, drug and cosmetic act and 35 U.S.C. 271(e) and 35 U.S.C. 156 of the patent act

    Google Scholar 

  • U.S. Code of Federal Regulations. Title 21 Part 320 bioavailability and bioequivalence. (Revised as 01 January 2012) U.S. Government Printing Office, Washington

    Google Scholar 

  • http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=320&showFR=1. Accessed 18 Nov 2013

  • U.S. Food and Drug Administration (2009) Requests the commissioner of food & drugs not approve any generic equivalent version of the petitioner’s proprietary drug product derma-smoothe/FS (Fluocinolone acetonide 0.01 % topical oil) unless & until applicants comply with statutory requirements [Docket No. FDA-2004-P-0215]. Regulations.gov, http://www.regulations.gov/#!home. Accessed 18 Nov 2013

  • U.S. Food and Drug Administration (2012) 50 Years: The Kefauver-Harris Amendments. U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/Drugs/NewsEvents/ucm320924.htm. Accessed 18 Nov 2013

  • Weiss SC (2011) Conventional topical delivery systems. Dermatol Ther 24(5):471–476

    Article  PubMed  Google Scholar 

  • Wosicka H, Cal K (2010) Targeting to the hair follicles: current status and potential. J Dermatol Sci 57(2):83–89

    Article  CAS  PubMed  Google Scholar 

  • Zhao J, Lui H, McLean DI, Zang H (2008) Integrated real-time raman system for clinical in vivo skin analysis. Skin Res Technol 14(4):484–492

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA

    April C. Braddy & Dale P. Conner

Authors
  1. April C. Braddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dale P. Conner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to April C. Braddy .

Editor information

Editors and Affiliations

  1. Office of Pharmaceutical Science, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Silver Spring, Maryland, USA

    Lawrence X. Yu

  2. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Generic Drugs, Silver Spring, Maryland, USA

    Bing V. Li

Rights and permissions

Reprints and permissions

Copyright information

© 2014 The United States Government

About this chapter

Cite this chapter

Braddy, A.C., Conner, D.P. (2014). Bioequivalence for Topical Drug Products. In: Yu, L., Li, B. (eds) FDA Bioequivalence Standards. AAPS Advances in the Pharmaceutical Sciences Series, vol 13. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1252-0_13

Download citation

Publish with us

Policies and ethics

Search

Navigation